skip to Main Content

Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care

Optimizing Application of Genomic Analyses Critical to Advancing Pancreatic Cancer Care
Molecular abnormalities, such as BRCA1/2, ATM, CHEK2, and microsatellite instability (MSI), are a handful of subtypes emerging in pancreatic cancer research, but the way these are identified and targeted with treatment still requires further investigation, said Diane M. Simeone, MD.

“Now we understand that there are some emerging subtypes of pancreatic cancer that we want to think about treating differently,” said Simeone, director of the Pancreatic Cancer Center at NYU Langone’s Perlmutter Cancer Center. Read more . . . 


Back To Top